Dr. Tao Sun 孙涛
Chief Physician
Department of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Neoadjuvant, adjuvant, salvage chemotherapy, endocrine and biological therapies for breast cancer, lung cancer, malignant lymphoma, and digestive tract tumors. Focuses on postoperative adjuvant therapy based on breast cancer receptor and gene expression profiles.
Dr. Sun is a Chief Physician and medical doctor holding a State Council special allowance. Trained at Kyushu National Cancer Center (Japan) and Jozef Stefan Institute (Slovenia). Leads the Breast Medical Department at Liaoning Cancer Hospital. Has published 23 SCI papers as first or corresponding author and leads or participates in 25 national and provincial research projects.
Professional roles
- Standing Committee Member, Breast Cancer Professional Committee, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Tumor Cardiology Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Secretary-General and Standing Committee Member, Tumor Marker Professional Committee, China Anti-Cancer Association
- Chair, Tumor Marker Professional Committee, Liaoning Anti-Cancer Association
Name order: in Chinese the family name comes first (Sun Tao). Papers usually list the name as Tao Sun or Sun T.
Selected publications
164 papers on PubMed matched by name and affiliation; 29 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Biol Med, 2026 (senior author): Erratum to From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management. PubMed 42717681
- Cancer Cell Int, 2026 (senior author): The novel oleanolic acid derivative ZQL-4c modulates trastuzumab resistance in HER2+ breast cancer by inhibiting SCD-mediated lipid metabolism disorders. PubMed 42343365
- Genesis, 2026 (senior author): Role of BARX1 in Development and Disease. PubMed 41840842
- Cancer, 2026 (senior author): The safety of trastuzumab deruxtecan (T-DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta-analysis. PubMed 41620925
- Breast Cancer Res, 2026 (senior author): BHLHE22, targeted by deubiquitinating enzyme OTUD3, exerts an antitumor role in triple-negative breast cancer progression via transcriptionally inhibiting CDT1. PubMed 41484895
- Ann Med, 2025 (senior author): The impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer. PubMed 41346024
- Cancer Biol Med, 2025 (senior author): From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management. PubMed 41321049
- Chin Med J (Engl), 2025 (senior author): ZQL-4c exerts anti-tumor effects by specifically targeting SCD1 in triple-negative breast cancer both in vitro and in vivo. PubMed 40691103
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion